appendix 3b new shares, page-63

"This would be a perfect situation for a bigger player who may know better. A stock with verified potential but undervalued."

I hear what you are saying dontaskme, but I am hoping that any offers are not entertained by Prana for a long time yet. Having worked in bigpharma for quite some time, I don't want to see the wonderful potential of a PBT2 or other compounds (Parkinsons, MPAC library etc.) with the potential impact of huge SP multiples on current pricing swallowed up at maybe 1-2 times current price to feed a greedy company which is merely aiming to maximise the value of multiple brands competing for limited marketing dollars and feed its pipeline into the future. Have a look at the dispute between Biota and Glaxo to see what I mean.

With a significantly derisked compound in PBT2 in 2 separate indications, I'd much rather that Prana went on its own for as long as possible before cashing in to much larger companies if required (and then only through astute licensing deals) for large Phase 3/4 or market launch activities.

Just my opinion.